Anti-IL-13 Reference Antibody (abrezekimab) is used as a research tool in the study and development of therapies targeting interleukin-13 (IL-13), a key cytokine involved in chronic inflammation, particularly in allergic conditions and respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). This antibody inhibits IL-13 function, enabling evaluation of the impact of blocking IL-13 signaling on inflammation and tissue damage.

In drug development, this reference antibody serves as a standard for comparing the efficacy of commercial antibodies or novel therapeutics designed for the same target, ensuring specificity and reliable inhibitory activity. It is also employed in quality control processes for therapeutic antibody production to assess purity, stability, and biological activity.

In bioanalytical applications, such as ELISA or cytokine level detection in biological samples, this reference antibody acts as a positive control or for calibrating assay systems, ensuring accurate and reproducible experimental results across studies.